Dr. Sager joins after 18 months as part-time CMO, in which he built the clinical…
Nathan BotelhoSeptember 29, 2022
News
CAMBRIDGE, Mass. — September 19, 2022: Angiex, developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for…
Nathan BotelhoSeptember 19, 2022
Company provides background on its technology platform and AGX101, its lead assetCAMBRIDGE, Mass. — September…
AngiexSeptember 6, 2022
Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive…
AngiexJune 22, 2022